

A close-up photograph of a woman's arm and hand. She is wearing a light-colored, ribbed, short-sleeved dress. Her right arm is bent at the elbow, and her hand is resting on her forearm. There is a prominent, reddish, scaly, and inflamed patch on her elbow, characteristic of psoriasis. The background is a plain, light color.

Get to
know us

Contents



Our World

**Our focus on Medical
Dermatology**

**Research &
Development**

**Environmental, Social,
and Governance**

**Innovation that
transforms patients'
lives**

Digital Garden

We are Ammirall, a global biopharmaceutical company focused on **Medical Dermatology**, passionate about science and committed **to transform the patients' world.**

We collaborate with scientists and healthcare professionals and invest in differentiated and groundbreaking Medical Dermatology products to bring our innovative solutions to patients in need.



Our Noble Purpose

Transform the patients' world by helping them realize their hopes and dreams for a healthy life.

Our commitment



Deliver Medical Dermatology solutions that impact patients' lives



Solidify Ammirall as a global leader in Medical Dermatology



Enhance our focus on innovation by investing in transformative therapies that meet patients' needs



Reduction of our carbon footprint and mitigation of climate change's effect

Our World



Key financial indicators 2021

Total Revenues

€836.5 MM

Net Sales

€827.2 MM

Normalised Net Income


€81.4 MM

EBITDA

€235.6 MM

Operating Cash Flow

€233.8 MM




Our focus on Medical Dermatology

Our dedication to patient needs is a clear driving force to our success. Now a world leader in Medical Dermatology, we are extremely proud to see patients across the world benefit from Almirall's achievements.

Skin diseases are ranked as the fourth most common cause of human illness. Each year Almirall is at the forefront of dermatological medical advances and this year has been no exception. Our five core axes continue to be actinic keratosis, atopic dermatitis, psoriasis, acne, and onychomycosis.

Top dermatology products by sales in MM€ (2021)



Psoriasis

Skilarence® (dimethyl fumarate)

Ilumetri® (tildrakizumab)

Wynzora® (calcipotriol, betamethasone dipropionate)



Acne

Seysara® (sarecycline)

Aczone® (dapsone)



Actinic keratosis

Actikerall® (salicylic acid, 5-fluorouracil)

Solaraze® (diclofenac sodium)

Klisyri® (tirbanibulin)



Atopic dermatitis

Cordran® Tape (USP, flurandrenolide)



Onychomycosis

Ciclopoli® (ciclopirox)

Looking beyond Dermatology: other key therapeutic areas

At Almirall, our perceptive and engaged management style has continually built on meeting patient needs. In doing so, the need for diversification has always been recognised. While our primary focus continues to be on Medical Dermatology, our portfolio extends beyond this. Indeed, we continue to develop and define priorities to meet market needs and remain agile.



Other strategic products*

Our current portfolio provides medical solutions in fields such as neurology, cardiology, and gastroenterology. In covering such a wide spectrum, we have been able to continue strengthening our mission to have a positive impact on patient lives across the world.

Actithiol® (carbocisteine + promethazine)

Airtal® (aceclofenac)

Almax® (almagate)

Almogran® (almotriptan)

Cleboril® (clebopride)

Crestor®/**Provisacor**® (rosuvastatin)

Dobupal® (venlafaxine)

Ebastel® (ebastine)

Elecor® (eplerenone)

Efficib® (sitagliptin + metformin)

Hidroxil® (vitamins B1 + B6 + B12)

Imunorix® (pidotimod)

Parapres® (candesartan)

Rinastel® (sea water + aloe vera and chamomile)

Silodyx® (silodosin)

Synflex® (naproxen)

Macmiror® (nifuratel + nystatin)

Rinastel® (sea water + xylitol)

Sativex® (dronabinol + cannabidiol)

Spagulax® (ispaghula)

Tesavel® (sitagliptin)

* Some of these products may not be available in some countries of the EU.

Environmental, Social, and Governance

Our approach to ESG

At Almirall, we view sustainability as a commitment to creating economic, social, and environmental value for our stakeholders, so that we may make a significant impact and contribute to the development of a healthy society. Our approach to Environmental, Social, and Governance (ESG) helps us move forward in our purpose. The principles, established within our Policy on Sustainability and approved by the Board of Directors, lay a solid foundation to act with environmental, social, and governance responsibility.

Environmental	Social	Governance
Reduction in greenhouse gas emissions (location-based) during the period 2014-2021: 39%	Number of employees 1,786	Sustainalytics' ESG Rating 21.5 Medium risk
Renewable energy consumption in 2021: 55%	53% Women 47% Men	ESG aspects incorporated into the variable remuneration of the Management Board
Energy Efficiency Reduction of energy consumption between 2019-2021: 6%		ESG Risks included in the Top 15 Corporate Risks (Climate Change and Talent Management)
Alignment of our climate-related strategy, with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD)	Total training hours 19,297	Revision of the Anti-Bribery and Anti-Corruption Policy and Code of Ethics and launch of the internal whistleblowing channel SpeakUp!
Definition of a decarbonisation programme that sets ambitious medium and long-term value-chain targets aligned with the 1.5°C scenario	Nationalities represented 26	Platinum medal in the Ecovadis Sustainability Rating

Our ESG Plan 2021-2023

<p>Environment</p>	<p>Climate change strategy Carbon footprint and reduction targets Energy efficiency management</p>	
<p>Social</p>	<p>Corporate social action framework Supplier risk management & Sustainable Procurement Patient engagement Diversity, Equity, and Inclusion Employees engagement in social initiatives Occupational health, safety, and wellbeing</p>	
<p>Governance</p>	<p>Anti-corruption and anti-bribery policy ESG risk management Code of Ethics and whistleblowing channels</p>	
<p>Management and communication</p>	<p>ESG Governance and Dashboards External ESG initiatives ESG communication</p>	

Innovation that transforms patients' lives

Almirall SHINE: Driving sustainable innovation

At the beginning of 2021, we launched **SHINE**, a research driven initiative aiming to boost dermatology innovation by promoting collaborations with centres of excellence worldwide.

With 85 currently identified centres of excellence and around 100 medical physician scientists, this is a powerful means to identify new targets for diseases that currently lack medical solutions. Through SHINE, in 2021, we forged three new research collaborations with first-class institutions. These are with the University of Michigan (US), University of Dundee (Scotland), and Goethe Institute of Frankfurt (Germany).

AlmirallShare: Being at the heart of research

In 2017, we launched **AlmirallShare**, an open innovation platform that facilitates partnering opportunities and accelerates the generation of new treatments.

AlmirallShare has attracted more than 1,100 scientists and has received 560 proposals. We have to date 8 collaborative projects with 7 institutions. These include collaborations for new therapies (IDIBAPS, University of Turin, University of South Australia, Hospital de la Santa Creu i Sant Pau), new targets (Dublin City University, University of Namur), and new preclinical models (University College Dublin, University of Sheffield).

Almirall SHINE




AlmirallShare

Digital Garden

Almirall launched the **Digital Garden**, its dermatology digital health accelerator, in 2020 to accelerate the growth of start-ups that offer innovative technology-based services and solutions throughout the patient journey.

The initiative, hosted at the Barcelona Health Hub, consists of a **mentorship programme paired with academic and hands-on sessions** from the Digital Garden network of global partners. With the in-house incubator programme, Almirall wants to be closer to those technologies with the potential of disrupting the health space such as AI for image recognition, digital therapeutics, digital companions or platforms. The programme also wants to foster an entrepreneurial mindset within Almirall's teams.

Participating start-ups



Feel the Science